Skip to main content

Table 3 Univariate risk factors for early parasitaemia positivity rates in Asia

From: Early parasitological response following artemisinin-containing regimens: a critical review of the literature

 

Day 1

Day 2

Day 3

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

Age

1.03 (0.95-1.12)

0.474

0.96 (0.89-1.02)

0.185

0.85 (0.79-0.92)

<0.001

Log e parasitaemia

2.42 (1.58-3.70)

<0.001

3.11 (1.86-5.20)

<0.001

8.20 (3.97-16.97)

<0.001

Year

0.98 (0.82-1.16)

0.789

0.99 (0.76-1.30)

0.959

1.43 (1.07-1.91)

0.015

Artemisinin derivative

 

<0.001

 

0.904

 

0.231

Artemether

1.00

 

1.00

 

1.00

 

Artemisinin

ND

 

1.45 (0.25-8.43)

0.676

ND

 

Artesunate

0.83 (0.68-1.01)

0.058

1.06 (0.72-1.56)

0.784

3.85 (0.73-20.30)

0.113

DHA

0.50 (0.40-0.62)

<0.001

0.97 (0.63-1.50)

0.904

3.39 (0.59-19.59)

0.173

Treatment

 

<0.001

 

0.778

 

0.592

DHA+PIP

1.00

 

1.00

 

1.00

 

AL

2.04 (1.62-2.57)

<0.001

1.02 (0.66-1.57)

0.934

0.29 (0.05-1.67)

0.167

AS+MQ

1.64 (1.36-1.98)

<0.001

1.09 (0.85-1.41)

0.487

1.16 (0.65-2.06)

0.620

AS+SP

0.46 (0.12-1.86)

0.279

0.09 (0.003-2.68)

0.166

ND

 

AS+AQ

0.66 (0.11-4.04)

0.654

0.45 (0.03-5.94)

0.547

2.28 (0.16-32.22)

0.543

AS alone

ND

 

1.25 (0.64-2.45)

0.512

1.45 (0.59-3.54)

0.414

  1. Only patients who received artemisinin derivative until Day 1 (2 or 3) are included for analysis of PPRday1 (2 or 3). Study arms with rectal artesunate are excluded. Positivity rate equal to 0% on Day 2 was carried forward to Day 3 if Day 3 rate was not reported.
  2. ND= There were no patient data available or patients with detectable parasitaemia in this category so the OR could not be estimated. P-value = 0.623 for comparison with DHA+PIP treatment (Fisher’s exact test). For the purpose of logistic model this treatment group was merged with all other treatments (not included in the listed categories).
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us